Connect
MJA

    Diagnosis and management of heparin‐induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group

    Joanne Joseph, David Rabbolini, Anoop K Enjeti, Emmanuel Favaloro, Marie‐Christine Kopp, Simon McRae, Leonardo Pasalic, Chee Wee Tan, Christopher M Ward and Beng H Chong
    Med J Aust 2019; 210 (11): . || doi: 10.5694/mja2.50213
    Published online: 17 June 2019

    Abstract

    Introduction: Heparin‐induced thrombocytopenia (HIT) is a prothrombotic disorder that occurs following the administration of heparin and is caused by antibodies to platelet factor 4 and heparin. Diagnosis of HIT is essential to guide treatment strategies using non‐heparin anticoagulants and to avoid unwanted and potential fatal thromboembolic complications. This consensus statement, formulated by members of the Thrombosis and Haemostasis Society of Australia and New Zealand, provides an update on HIT pathogenesis and guidance on the diagnosis and management of patients with suspected or confirmed HIT.

    Main recommendations:

    • A 4Ts score is recommended for all patients with suspected HIT prior to laboratory testing.
    • Further laboratory testing with a screening immunoassay or confirmatory functional assay is not recommended in individuals with a low 4Ts score. However, if there are missing or unreliable clinical data, then laboratory testing should be performed.
    • A positive functional assay result confirms the diagnosis of HIT and should be performed to confirm a positive immunoassay result.
    • Heparin exposure must be ceased in patients with suspected or confirmed HIT and initial treatment with a non‐heparin alternative instituted.
    • Non‐heparin anticoagulants (danaparoid, argatroban, fondaparinux and bivalirudin) used to treat HIT should be given in therapeutic rather than prophylactic doses.
    • Direct oral anticoagulants may be used in place of warfarin after patients with HIT have responded to alternative parenteral anticoagulants with platelet count recovery.

     

    Changes in management as a result of this statement:

    • These are the first Australasian recommendations for diagnosis and management of HIT, with a focus on locally available diagnostic assays and therapeutic options.
    • The importance of examining both clinical and laboratory data in considering a diagnosis of HIT cannot be overstated.

     

    • Joanne Joseph1,2
    • David Rabbolini3,4
    • Anoop K Enjeti5
    • Emmanuel Favaloro6,7
    • Marie‐Christine Kopp4
    • Simon McRae8
    • Leonardo Pasalic6,7
    • Chee Wee Tan8
    • Christopher M Ward3,4
    • Beng H Chong9

    • 1 St Vincent's Hospital, Sydney, NSW
    • 2 St Vincent's Clinical School, University of New South Wales, Sydney, NSW
    • 3 Royal North Shore Hospital, Sydney, NSW
    • 4 Northern Blood Research Centre, Kolling Institute of Medical Research, Sydney, NSW
    • 5 Calvary Mater Hospital, Sydney, NSW
    • 6 Institute of Clinical Pathology and Medical Research, Sydney, NSW
    • 7 Westmead Hospital, Sydney, NSW
    • 8 Royal Adelaide Hospital, Adelaide, SA
    • 9 St George Hospital, Sydney, NSW

    Correspondence: Joanne.Joseph@svha.org.au
    Competing interests:

    Anoop Enjeti has received speaker fees from Bayer and Sanofi Aventis outside the submitted work. Simon McRae has received research funding from CSL and Roche outside the submitted work. Chee Wee Tan has received non‐financial support from Bayer Health and speaker fees from Pfizer outside the submitted work. Christopher Ward has received personal fees and non‐financial support from Aspen, personal fees from Instrumentation Laboratory (Werfen) and personal fees from Sanofi during the preparation of this consensus statement.

    Author
    remove_circle_outline Delete Author
    add_circle_outline Add Author
    Comment
    Do you have any competing interests to declare? *
    I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
    I/we agree to the Terms of use of the Medical Journal of Australia *
    Email me when people comment on this article
    Online responses are no longer available. Please refer to our instructions for authors page for more information.